Following publication of a landmark trial, such as the Pneumatic Retinopexy Versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT) study,1 there is a strong desire to see if the results of the trial can be replicated in clinical practice, the so-called real-world setting. Participants in randomized clinical trials are usually healthier and have fewer comorbidities than the patients in our clinics. The study by Yannuzzi and colleagues2 in this issue of JAMA Ophthalmology attempts to address that need.